Therapeutic agent for facioscapulohumeral muscular dystrophy

A pharmaceutical composition with ambroxol hydrochloride addresses the lack of cure for FSHD by suppressing DUX4 in FSHD2 through epigenetic intervention, enhancing muscle differentiation and strength.

WO2026235160A1PCT designated stage Publication Date: 2026-11-12ASAGI LABS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/017451
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is currently no established cure for facioscapulohumeral muscular dystrophy (FSHD), and existing treatments only provide symptomatic relief, with drugs targeting the DUX4 protein predicted to be effective for both FSHD1 and FSHD2 showing surprising efficacy specifically for FSHD2.

Method used

A pharmaceutical composition comprising an expectorant, a pharmaceutically acceptable salt, or a solvate thereof, such as ambroxol hydrochloride, is used to treat FSHD, intervening in the epigenetic abnormalities of FSHD2 by suppressing DUX4 activity through a network of epigenetic abnormalities.

Benefits of technology

Ambroxol hydrochloride effectively reduces DUX4 target genes and restores muscle differentiation markers, indicating potential as a disease-modifying drug for FSHD2 by stabilizing mutated SMCHD1 protein and re-heterochromatinizing the genome, thereby improving muscle strength and function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2026017451_12112026_PF_FP_ABST
    Figure JP2026017451_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to provide a pharmaceutical composition for treating facioscapulohumeral muscular dystrophy. The present invention provides a pharmaceutical composition for treating facioscapulohumeral muscular dystrophy, said pharmaceutical composition comprising an expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Therapeutic agent for facioscapulohumeral muscular dystrophy

[0001] The present invention relates to a pharmaceutical composition for treating facioscapulohumeral muscular dystrophy.

[0002] Ambroxol hydrochloride (generic name: Mucosolvan) promotes the secretion of secretions in the lungs and respiratory tract, and enhances ciliary movement to facilitate expectoration of sputum. It also stimulates the production of pulmonary surfactant, a substance that acts as a lubricant for the respiratory tract mucosa, lubricates the respiratory tract wall, and has the effect of facilitating sputum expectoration. In previous studies, the effect of administering ambroxol hydrochloride in suppressing the age- and drug-related decrease in muscle mass and muscle strength and maintaining muscle function has been confirmed in animal models (Patent Document 1).

[0003] Facioscapulohumeral Muscular Dystrophy (FSHD) is a type of hereditary muscular dystrophy in which muscle weakness mainly starts in the muscles of the face, shoulders and upper arms, and gradually progresses to the lower limbs. It is caused by the abnormal expression of the DUX4 gene located in a specific region of chromosome 4. Although it is a relatively rare disease in Japan, it is considered the second most common muscular dystrophy after Duchenne muscular dystrophy in Europe and the United States, and affects both men and women. FSHD generally has an onset during adolescence to young adulthood (late teens to 30s), and some patients may develop symptoms during childhood (under 10 years old). On the other hand, mild cases may be diagnosed after the age of 40, and there are individual differences in the age of onset and progression rate.

[0004] The symptoms of FSHD usually show a characteristic pattern of progressing from the cranial side (face / shoulders) to the caudal side (feet). Symptoms in the upper limbs and face (early stage): difficulty closing the eyes, difficulty opening the mouth wide, inability to make a proper smile (muscle weakness of the facial muscles), difficulty raising the arms, the scapula appears prominent (scapular winging), the muscles of the upper arm become thin, making it difficult to lift objects. Symptoms in the lower limbs (progressive stage): muscle weakness in the thighs and calves, gait disturbance, difficulty climbing stairs, and in severe cases, there is a possibility of falls and wheelchair use.

[0005] Symptoms often appear asymmetrically, and muscle weakness progresses slowly, allowing many patients to maintain their daily lives for extended periods. Currently, there is no established cure for FSHD. Therefore, symptomatic treatments such as physical therapy, exercise therapy, and occupational therapy are necessary to slow the progression of symptoms and maintain quality of life.

[0006] International Public Gazette 2023 / 145735 pamphlet

[0007] Therefore, the present invention aims to provide a pharmaceutical composition for treating facioscapulohumeral muscular dystrophy.

[0008] Through diligent research, the inventors have discovered that expectorants, pharmaceutically acceptable salts thereof, or solvates thereof can serve as active ingredients in pharmaceutical compositions for treating facioscapulohumeral muscular dystrophy.

[0009] In other words, the present invention provides the following: [Aspect 1] A pharmaceutical composition for treating facioscapulohumeral muscular dystrophy, comprising an expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof. [Aspect 2] The pharmaceutical composition according to Aspect 1, wherein the expectorant comprises ambroxol. [Aspect 3] The pharmaceutical composition according to Aspect 1, wherein the expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof is ambroxol hydrochloride represented by the following formula.

[0010] According to the present invention, facioscapulohumeral muscular dystrophy can be treated.

[0011] FSHD1 and FSHD2 have nearly identical clinical phenotypes (progression and distribution of muscle atrophy), and also share common downstream pathologies (abnormal expression of DUX4). Therefore, a typical person skilled in the art (researcher) would predict that drugs that suppress DUX4 should be effective for both FSHD1 and FSHD2. However, the data from the following examples show a surprising result that could not have been predicted from the clinical similarities: while effective for FSHD1, it was particularly effective for FSHD2.

[0012] The mechanism by which Ambroxol suppresses DUX4, rather than directly inhibiting the DUX4 protein, by intervening in a network of epigenetic abnormalities specific to FSHD2 (such as SMCHD1 mutations), is difficult to deduce logically from existing knowledge of Ambroxol (expectorant effect, glucocerebrosidase chaperone effect, etc.).

[0013] Ambroxol shows therapeutic efficacy in cells derived from FSHD1 and FSHD2 patients. Composite score of DUX4 target genes: When DUX4 activity decreases, the following markers also decrease, and can therefore be used for pharmacodynamic evaluation. ZSCAN4: Unchanged or decreased in FSHD2; MBD3L2: Slightly decreased in FSHD1; Clearly decreased in FSHD2; TRIM43: Unchanged or decreased in FSHD2. Ambroxol shows therapeutic efficacy in cells derived from FSHD1 and FSHD2 patients. DUX4 suppresses muscle fiber formation by repressing genes such as MYH3. MYH3: Increased in FSHD2.

[0014] The present invention provides a pharmaceutical composition for treating facioscapulohumeral muscular dystrophy, comprising an expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof.

[0015] Ambroxol is an example of an expectorant.

[0016] Examples of expectorants, pharmaceutically acceptable salts thereof, or solvates thereof include ambroxol hydrochloride, represented by the following formula. Furthermore, the compound represented by the following formula has the common name ambroxol hydrochloride, and its molecular formula is, for example, C 13 H 18 Br 2 N 2 It is represented as O·HCl.

[0017] Examples of pharmaceutically acceptable salts include basic salts and acidic salts, which can be obtained by reacting the expectorant in the present invention with a base or acid when it has an acidic or basic group.

[0018] Examples of pharmaceutically acceptable salts include basic salts such as alkali metal salts like sodium salts, potassium salts, and lithium salts; alkaline earth metal salts like magnesium salts and calcium salts; organic base salts such as N-methylmorpholine salt, triethylamine salt, tributylamine salt, diisopropylethylamine salt, dicyclohexylamine salt, N-methylpiperidine salt, pyridine salt, 4-pyrrolidinopyridine salt, and picoline salt; or amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate salt, and aspartate salt.

[0019] Examples of acidic salts include hydrohalides such as hydrofluoric acid, hydrochloride, hydrobromide, and hydroiodide; inorganic salts such as nitrates, perchlorates, sulfates, and phosphates; lower alkanesulfons such as methanesulfonates, trifluoromethanesulfons, and ethanesulfons; arylsulfons such as benzenesulfonates and p-toluenesulfonates; organic salts such as acetates, malates, fumarates, succinates, citrates, ascorbic acid, tartrates, oxalates, and maleates; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamates, and aspartates.

[0020] Examples of solvates include hydrates, alcoholic dihydrates, aprotic solvates, THF (tetrahydrofuran) dihydrates, acetonitrile dihydrates, and DMSO-THF dihydrates.

[0021] As shown in the examples below, facioscapulohumeral muscular dystrophy in subjects can be treated with expectorants, pharmaceutically acceptable salts thereof, or solvates thereof as active ingredients.

[0022] Examples of subjects include vertebrates. Examples of vertebrates include mammals such as mice, rats, rabbits, pigs, cattle, monkeys, and humans. Mammals are preferably humans. Subjects may be of any age, including infants, young people, adolescents, adults, and the elderly.

[0023] Treatment for facioscapulohumeral muscular dystrophy includes, for example, the treatment of facioscapulohumeral muscular dystrophy and the prevention of facioscapulohumeral muscular dystrophy. Treatment for facioscapulohumeral muscular dystrophy includes, for example, complete cure of facioscapulohumeral muscular dystrophy and alleviation of its symptoms.

[0024] The pharmaceutical composition of the present invention may consist of an expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof, or it may be formulated as a pharmaceutical composition mixed with a pharmaceutically acceptable carrier.

[0025] The pharmaceutical composition may be formulated in a dosage form for oral use or in a dosage form for parenteral use. Examples of dosage forms include, but are not limited to, tablets, capsules, powders, granules, liquids, suspensions, injections, patches, poultices, ointments, etc.

[0026] Examples of pharmaceutically acceptable carriers include solvents such as sterile water and physiological saline; binders such as gelatin, corn starch, tragacanth gum, and gum arabic; excipients such as crystalline cellulose; and leavening agents such as corn starch, gelatin, and alginic acid.

[0027] Examples of pharmaceutically acceptable carriers include additives. These additives include lubricants such as magnesium stearate; sweeteners such as sucrose, lactose, and saccharin; flavoring agents such as peppermint and red ginger oil; stabilizers such as benzyl alcohol and phenol; buffering agents such as phosphates and sodium acetate; solubilizers such as benzyl benzoate and benzyl alcohol; antioxidants; preservatives; surfactants; and emulsifiers.

[0028] The pharmaceutical composition can be formulated by appropriately combining the above-mentioned carriers and mixing them in a unit dose form generally accepted for pharmaceutical production.

[0029] When the pharmaceutical composition is an injectable preparation, suitable solvents for injection include, for example, physiological saline, glucose, D-sorbitol, D-mannose, D-mannitol, sodium chloride, and other adjuvants in an isotonic solution. The solvent for injection may also contain alcohols such as ethanol; polyalcohols such as propylene glycol and polyethylene glycol; and nonionic surfactants such as polysorbate 80 (trademark) and HCO-50.

[0030] The pharmaceutical composition of the present invention may be administered orally, parenterally, or rectally, and the daily dose will vary depending on the type of compound, the method of administration, the patient's symptoms, age, etc. For example, in the case of oral administration, typically about 0.01 to 1000 mg per kg of human or mammalian body weight, more preferably about 0.1 to 500 mg, can be administered in one to several divided doses. In the case of parenteral administration such as intravenous injection, typically, for example, about 0.01 mg to 300 mg per kg of human or mammalian body weight, more preferably about 1 mg to 100 mg can be administered.

[0031] The present invention provides a method for treating facioscapulohumeral muscular dystrophy in a subject, characterized by administering an expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof to the subject.

[0032] The present invention provides a pharmaceutical composition for use in the treatment of facioscapulohumeral muscular dystrophy in a subject, comprising an expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient.

[0033] The present invention provides the use of expectorants, pharmaceutically acceptable salts thereof, or solvates thereof in the preparation of pharmaceutical compositions for use in the treatment of facioscapulohumeral muscular dystrophy in subjects.

[0034] Furthermore, the pharmaceutical composition for treating facioscapulohumeral muscular dystrophy of the present invention may be a therapeutic agent containing ambroxol as the active ingredient, targeting FSHD2 patients who have a normal D4Z4 repeat length and mutations in epigenetic regulatory factors such as SMCHD1.

[0035] Study Design: <Inclusion Criteria> Patients who meet all of the following criteria are eligible: • Confirmed diagnosis of FSHD1 or FSHD2 by genetic testing. • Able to walk, and able to walk 10 meters with or without the use of assistive devices (canes, walking sticks, braces, etc.). • Ricci Clinical Severity Scale score of 2.5 or higher and 4 or lower. • Agree to maintain the frequency and intensity of physical therapy, occupational therapy, and other exercise therapy throughout the clinical trial period.

[0036] <Exclusion Criteria> Participants in this study are ineligible if any of the following apply: • Pregnant, planning to become pregnant during the study period, or breastfeeding. • Unwilling or unable to comply with contraceptive requirements. • BMI (Body Mass Index) of 35.0 kg / m² at the time of screening. 2 The following conditions must be met: • The expected life expectancy is less than 2 years. • There is a contraindication to MRI (magnetic resonance imaging). • The physician or sponsor determines that participation in the study is inappropriate or would hinder participation in or completion of the study due to abnormal test results, medical history, disease, etc., and the patient has used the investigational drug within one month of screening (or five times the drug's half-life, whichever is longer). • There is a clinically significant cardiovascular disease. • There are significant abnormal findings on echocardiography at the time of screening (however, mitral valve prolapse is not excluded). • The patient has developed a serious illness within one month prior to screening.

[0037] Evaluation items: - Change from baseline in RSA (Relative Surface Area) Q1-Q5 with 500g wrist weights attached to the dominant and non-dominant arms (evaluated by Reachable Workspace: RWS) *RWS (Reachable Workspace) is a clinical index that evaluates the relative surface area within reach of the outstretched arm. The score is evaluated from 0 (no reach) to 1.25 (maximum). A higher score indicates a better result. - Change in peak VO2 12 weeks after the start of intervention treatment *Peak VO2 represents Peak Oxygen Uptake, which indicates the maximum oxygen consumption. • Individual goal achievement using visual score • Relationship between steps exceeding target heart rate and changes in peak VO2 • Relationship between number of resistance training sessions and changes in peak VO2 • Fitbit wearing time estimated from heart rate data • Changes in the following items in the exercise support program intervention group and the standard treatment group: Total steps (weekly average) Number of days exceeding target steps (weekly average) Steps exceeding target heart rate (weekly average) Number of days exceeding target heart rate (weekly average) • Changes in the following items in the exercise support program intervention group: Number of resistance training sessions (weekly average) Intensity of resistance training Number of app launches (weekly average): Number of times morning condition assessment was answered • European Health Literacy Survey Questionnaire (HLS-EU-Q47) 12),13) Changes in the index score and EQ-5D-5L score *EQ-5D-5L (EuroQol 5 dimensions 5-level) is a questionnaire used to measure health-related quality of life (QOL). It evaluates five items, such as walking, getting dressed, daily activities, pain and discomfort, anxiety and depression, on a 5-point scale. - Comparison of step count data from activity tracker and Fitbit - Changes in walking ability (lateral pelvic movement, vertical movement, step length, gait cycle, walking speed) - Changes in center of gravity sway (perimeter area, rectangular area, effective area, total trajectory length) - Changes in grip strength (maximum grip strength using a digital grip strength meter) - Changes in SPPB - Changes in thigh circumference (15 cm above the patella) - Changes in knee extension muscle strength (knee extension torque using μTas)

[0038] (1) Safety evaluation items: Incidence of adverse events, Number of defects occurring

[0039] Test Method: This study is a multi-center, collaborative, blinded, randomized controlled trial. *A blinded randomized controlled trial is a clinical trial that verifies the efficacy and safety of drugs or medical devices, in which subjects are randomly divided into groups to compare the effects of different treatment methods. Since the trial is conducted in a manner that prevents physicians and patients from knowing which group they have been assigned to, the influence of bias can be reduced. The enrolled study subjects will be assigned to Group A (test drug group) or Group B (control drug group: placebo) via stratified randomization based on age, gender, and severity. For Group A (test drug group), 1 tablet (15.0 mg as ambroxol hydrochloride) will be orally administered 3 times a day. For Group B (control drug group: placebo), Placebo Pharma Placebo Plus 30 (placebo food / placebo) will be orally administered in the same manner, 1 tablet at a time, 3 times a day. Administration period: 4, 12, 36 weeks Number of cases: 40 cases Number of Visits, Flow

[0040] Test Items: The following are known to be altered in FSHD as blood biomarkers from the paper cited below, and will also be used as test items in this clinical trial. They serve as indicators of muscle destruction, regeneration, and inflammation.

[0041] C3, C4b, Factor D, and sC5b-9 The above are the complement terminal complex (membrane attack complex, MAC), which is a complex that forms pores in the cell membrane of pathogenic cells to destroy them when the complement system is activated. It is mainly composed of five complement components: C5b, C6, C7, C8, and C9, and is associated with the genes encoding these components. Paper (https: / / academic.oup.com / hmg / article / 31 / 11 / 1821 / 6464691?login=false).

[0042] IL-6 / TNF-α Both IL-6 and TNF-α are inflammatory cytokines, which are important proteins involved in immune responses and inflammation. IL-6 induces acute inflammatory responses, while TNF-α activates inflammatory responses by binding to TNF receptors. Paper (https: / / pmc.ncbi.nlm.nih.gov / articles / PMC10977382 / ).

[0043] CK-MB CK-MB is one of the isozymes of creatine kinase (CK), and is an enzyme specifically present in cardiac muscle. It is used for the diagnosis of myocardial infarction and evaluation of its severity. Specifically, since it leaks into the blood due to damage to cardiomyocytes, an increase in CK-MB level is useful for the early diagnosis of myocardial infarction.

[0044] PLAT, chemokine (C-C motif) ligand 2, EGF, VTN, CD 40 ligand Plasminogen activator is an enzyme that activates the protein plasminogen and converts it into the enzyme plasmin. In particular, t-PA (tissue plasminogen activator) is produced in vascular endothelial cells and plays an important role in dissolving blood clots. Epidermal Growth Factor (EGF) is a type of growth factor that promotes cell proliferation and differentiation, and is an important protein involved in the growth of epithelial cells such as those in the skin and mucous membranes. EGF binds to the cell surface receptor (EGFR) to promote cell proliferation and differentiation via intracellular signal transduction. CCL2, also called MCP-1 (monocyte chemoattractant protein 1), C-C motif chemokine ligand 2 is a type of cytokine belonging to the CC chemokine family. It plays a role in recruiting monocytes, memory T cells, dendritic cells, etc. to sites of inflammation and tissue injury. Vitronectin is a glycoprotein present in plasma and the extracellular matrix, and is an important protein involved in cell adhesion, migration, differentiation, and the like. It is known as a cell adhesion protein together with fibronectin, laminin and the like. CD40 ligand (CD40L) is a protein mainly expressed on activated T cells, and belongs to the TNF superfamily. CD40 ligand binds to CD40 to stimulate B cell proliferation and differentiation, and is involved in T cell-dependent B cell responses to antigens. Reference (https: / / pmc.ncbi.nlm.nih.gov / articles / PMC4332410 / ).

[0045] Protocol for evaluating muscle fiber differentiation and Ambroxol efficacy using patient-derived iPS cells: Cell lines and seeding (Day 0): iPS cells derived from FSHD1 and FSHD2 patients were used. Induction of muscle differentiation (Day 2-Day 6): From Day 2, the differentiation medium was changed to one based on KSRM (α-MEM + 5% KOSR). To strongly drive and maintain muscle differentiation, 100 μM 2-mercaptoethanol (2-ME), 10 ng / mL IGF-1, and 5 μM SB 431542 were added. Drug preparation and addition (Day 6): Ambroxol hydrochloride was dissolved in DMSO and serially diluted to create stock solutions. On Day 6, Ambroxol was added to the medium to final concentrations of 0.3 μM and 3.0 μM. Sample collection and evaluation (Day 8): 48 hours after drug treatment, the cell morphology of each well was recorded by photography, and RNA was immediately collected and used for subsequent gene expression analysis (quantification of DUX4 target genes and MYH3).

[0046] The results are shown in Figures 1 and 2.

[0047] Discussion: 1. Background of the pathophysiology and molecular mechanisms of FSHD1 and FSHD2: Facioscapulohumeral muscular dystrophy (FSHD) is a disease in which the toxic gene DUX4, which is normally suppressed in somatic cells, is abnormally expressed due to the relaxation of the chromatin structure of the D4Z4 repeat sequence located on the long arm of chromosome 4 (4q35), causing muscle breakdown. Although the clinical symptoms are similar, it is classified into two subtypes based on the upstream molecular mechanisms.

[0048] FSHD1 (approximately 95% of the total): This is caused by a "structural shortening" of the D4Z4 repeat sequence itself (normally 11 to 100 or more repeats reduced to 1 to 10). The physical deletion of the repeat (abnormality of the cis factor) prevents the maintenance of heterochromatin structure, leading to a breakdown of epigenetic repression and abnormal transcription of DUX4.

[0049] FSHD2 (approximately 5% of the total): The D4Z4 repeat length is normal (11 or more), but the cause is a gene mutation in epigenetic regulators (SMCHD1, DNMT3B, LRIF1, etc.) that cause chromatin aggregation. Dysfunction of these trans factors leads to decreased DNA methylation and chromatin relaxation in the D4Z4 region throughout the genome, resulting in the expression of DUX4.

[0050] 2. Basic and clinical significance of each biomarker and its relationship to DUX4: In FSHD research and clinical trials, directly quantifying the DUX4 protein itself is extremely difficult (because its expression level is very low and it exhibits "burst expression," which is transiently expressed in some cells). Therefore, downstream target genes of DUX4 and phenotypic markers of muscle differentiation are used as direct indicators for drug efficacy evaluation (Pharmacodynamics: PD markers) as an international standard.

[0051] • MBD3L2, ZSCAN4, TRIM43 (DUX4 target genes): These are genes that are normally expressed only during early embryonic development and are completely suppressed in adult somatic cells. When DUX4 acts as a transcription factor, these early embryonic genes are abnormally activated, causing cytotoxicity and apoptosis. • Use in basic research: Used as the most sensitive and reliable indicator (surrogate marker) to determine whether "DUX4 transcriptional activity is suppressed" in drug screening. • Use in clinical trials: Extracting RNA from muscle biopsy samples and confirming the decreased expression of these genes (DUX4 target gene signature) is a major biomarker evaluation item for the development of a cure (e.g., Fulcrum Therapeutics' losmapimod clinical trial).

[0052] • MYH3 (muscle differentiation and muscle fiber marker): This is an embroidic myosin heavy chain that is expressed during the initial differentiation process from myoblasts to myotubes. DUX4 inhibits myogenesis processes such as Pax7, so the expression of muscle differentiation markers is significantly reduced under FSHD conditions. • Importance: The confirmation of not only a decrease in DUX4 target genes (removal of toxicity) but also an increase in MYH3 expression means that the differentiation and regenerative capacity of muscle cells has actually been restored (rescued), which is an improvement in the phenotype and is extremely important data that directly relates to the maintenance and recovery of muscle strength in clinical practice.

[0053] 3. Importance of this data and potential as a therapeutic agent: This data indicates that Ambroxol has the potential to be not only a general therapeutic agent for FSHD, but also a "precision medicine specifically for FSHD2."

[0054] - View on FSHD1: Ambroxol's effect on MBD3L2 suggests it may compensate for the structural abnormality of the "physical deletion" of the D4Z4 repeat.

[0055] • Efficacy and potential for FSHD2: Administration of Ambroxol reduces DUX4 target genes (such as MBD3L2) in FSHD2, while simultaneously restoring MYH3. This means that Ambroxol's known chaperone function and autophagy-activating effect stabilize the mutated SMCHD1 protein or activate an unknown epigenetic compensatory mechanism, successfully re-heterochromatinization (silencing) only in FSHD2 genomes where the D4Z4 repeat length is preserved. It has extremely high potential as a disease-modifying drug (DMD) that intervenes in the root cause (epigenetic abnormality) of FSHD2.

Claims

1. A pharmaceutical composition for treating facioscapulohumeral muscular dystrophy, comprising an expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof.

2. The pharmaceutical composition according to claim 1, wherein the expectorant comprises ambroxol.

3. The pharmaceutical composition according to claim 1, wherein the expectorant, a pharmaceutically acceptable salt thereof, or a solvate thereof is ambroxol hydrochloride represented by the following formula.